VYNE Therapeutics reports FY2021 revenue $14.8M, net loss $73.3M; pipeline progress

VYNE Therapeutics Inc.

FY2021 revenue $14.8M (down 30% YoY); net loss $73.3M, adjusted net loss $65.2M; EPS -$1.42.
FMX114 Phase 1b showed acceptable safety/PK; Phase 2a top-line results expected Q2 2022.
VYN201 preclinical data in TH17, fibrosis, vitiligo models show significant improvement; IND/H2 2022.
Divested MST franchise to Journey Medical for $20M upfront + $5M in 1 yr + up to $450M milestones.
Prepaid $35M debt in Aug 2021; entered $30M equity purchase agreement with Lincoln Park Capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.